Skip to content

Clinical diagnostic test of miRNA markers in lung cancer

Clinical diagnostic test of lung cancer miRNA markers based on miRFLP platform to detect sputum and blood

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100049425
Enrollment
Unknown
Registered
2021-08-02
Start date
2021-08-04
Completion date
Unknown
Last updated
2022-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer

Interventions

markers&#32
based&#32
on&#32
and&#32
blood,testing&#32
Index test:miRFLP&#32
detection&#32
of&#32
lung&#32
cancer&#32

Sponsors

Sichuan Cancer Hospital and Institute
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 70 years, no gender-limited physical examination chest CT screening no positive nodules (positive nodules or calcified nodules; 2. Indeterminate nodules or non-calcified nodules, such nodules determine the follow-up principle according to the nature and size of the nodules, and determine whether to carry out clinical intervention according to the growth characteristics of the nodules during follow-up); 3. Volunteers who plan to undergo pulmonary nodule surgery.

Exclusion criteria

Exclusion criteria: 1. Patients with myocardial infarction, stroke and shock in the past 3 months; 2. Patients with severe cardiac insufficiency, severe arrhythmia, unstable angina pectoris, severe hypertension and hypertensive crisis (systolic blood pressure>200 mmHg diastolic blood pressure>100 mmHg) or patients with thoracoabdominal aortic aneurysm in the past 4 weeks; 3. Patients with pneumothorax and pneumothorax within 1 month after healing; 4. Patients with severe bullae, severe hypoxemia and severe respiratory failure; 5. Large hemoptysis in the past 4 weeks, seizures requiring drug treatment, on the day of pulmonary function test, on the day of fiberoptic bronchoscopy, and hemoptysis after biopsy (including blood in sputum); 6. Severe hyperthyroidism, low immunity, susceptible to infection; 7. Frail or myasthenia gravis patients; 8. Those who cannot cooperate, such as patients with severe cough, hemiplegia, facial paralysis, cerebral palsy, intellectual disability, deaf patients, those with a history of allergy to PE materials, pregnant or breastfeeding women; 9. The investigators believe that they are not suitable to participate in this clinical trial.

Design outcomes

Primary

MeasureTime frame
micro Ribonucleic Acid markers in lung cancer;

Countries

China

Contacts

Public ContactLi Qiang

Sichuan Cancer Hospital and Institute

liqiang1907@vip.sina.com+86 18908178887

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026